The Mycoplasma-derived lipopeptide MALP-2 is a potent mucosal adjuvant.

摘要: The adjuvanticity of MALP-2, a 2-kDa synthetic lipopeptide with macrophage-stimulatory activity, was evaluated in BALB/c mice using β-galactosidase (β-gal) as model antigen. When co-administered β-gal by either the intranasal (i.n.) or i.p. route, MALP-2 (0.5 μg) capable increasing β-gal-specific serum IgG titers 675–3,560-fold and 64–128-fold (i.p.), respectively, compared to immunization alone. Using almost maximal responses were already stimulated following first immunization, similar those observed 10 μg cholera toxin B subunit (CTB) adjuvant. mucosal immune system also effectively (p<0.05) when administered i.n. route (36% 23% IgA lung vaginal lavages, respectively). co-administration stronger cellular response than CTB, both submandibular lymph nodes spleen (p<0.05). analysis isotypes profiles cytokines secreted vitro re-stimulated cells showed that triggered dominant Th2-response pattern. A recruitment B220+ MAC-1+ an up-regulated expression MHC class I, CD80 (B7.1) CD54 (ICAM-1) nasal associated lymphoid tissues from treated mice. Taken together, our results demonstrated represents very promising adjuvant for delivery vaccine antigens.